Elevance Health (NYSE:ELV) Given New $393.00 Price Target at Robert W. Baird

Elevance Health (NYSE:ELV) had its price target upped by Robert W. Baird from $331.00 to $393.00 in a research report report published on Thursday, Marketbeat.com reports. They currently have a neutral rating on the stock.

ELV has been the subject of a number of other research reports. Wells Fargo & Company increased their target price on shares of Elevance Health from $391.00 to $492.00 and gave the company an “overweight” rating in a research report on Monday. Morgan Stanley upped their price target on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. UBS Group increased their price objective on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Leerink Partners set a $364.00 price objective on Elevance Health in a research report on Thursday, April 23rd. Finally, Bank of America boosted their target price on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Fifteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average target price of $439.43.

Elevance Health Stock Performance

ELV stock opened at $372.20 on Thursday. The firm has a market cap of $80.83 billion, a price-to-earnings ratio of 16.54, a PEG ratio of 2.20 and a beta of 0.67. The firm has a 50-day simple moving average of $399.65 and a two-hundred day simple moving average of $355.22. Elevance Health has a one year low of $273.71 and a one year high of $436.24. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.48 and a current ratio of 1.52.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business had revenue of $49.83 billion for the quarter, compared to analysts’ expectations of $48.88 billion. During the same period last year, the business earned $8.84 EPS. The company’s revenue was up .8% compared to the same quarter last year. On average, equities analysts forecast that Elevance Health will post 27.09 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is presently 29.26%.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Elevance Health

A number of hedge funds have recently bought and sold shares of the business. Sei Investments Co. raised its holdings in shares of Elevance Health by 7.7% during the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock valued at $63,666,000 after acquiring an additional 11,745 shares during the last quarter. Glenview Trust co boosted its stake in Elevance Health by 41.5% during the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after buying an additional 475 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Elevance Health by 6.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after purchasing an additional 4,272 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Elevance Health by 5.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after acquiring an additional 2,012 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in shares of Elevance Health by 111.8% during the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after purchasing an additional 23,180 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance Health beat Q2 estimates on both EPS and revenue, with EPS of $7.45 versus expectations around $6.21 and revenue of $49.83 billion topping forecasts. Business Wire release
• Positive Sentiment: The company raised full-year 2026 adjusted EPS guidance to at least $27.00, signaling management sees improving operating performance and better cost control ahead. Reuters article
• Positive Sentiment: Several analysts turned more constructive after the report, with price target increases from firms including Guggenheim, Barclays, Robert W. Baird, and Truist, which can support sentiment on the stock. Benzinga article
• Neutral Sentiment: Recent coverage and earnings-call transcripts highlight improving medical cost management and stronger CarelonRx revenues, but also note ongoing strain in parts of the business and a mixed operating backdrop. Earnings call transcript
• Negative Sentiment: Some reports pointed to margin pressure and softer membership trends, which appear to be weighing on the stock despite the earnings beat. MSN article
• Negative Sentiment: The company is also leaving more Medicaid markets, adding a strategic headwind that may temper enthusiasm about the near-term growth outlook. Yahoo Finance article

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.